BMP2–ERK–ATF4 Axis-Based 6-methoxybenzofuran Compound I-9 Acts as Candidate Drug for Bone Formation and Anti-Osteoporosis

Ziying Zhou,Chenxi Zhao,Siyan Li,Xiaoyang Han,Jiangyi Zhu,Situ Xue,Zhuorong Li
DOI: https://doi.org/10.3390/ijms25063350
IF: 5.6
2024-03-16
International Journal of Molecular Sciences
Abstract:As the global population ages, the number of patients with osteoporosis is rapidly rising. The existing first-line clinical drugs are bone resorption inhibitors that have difficulty restoring the bone mass of elderly patients to the safe range. The range and period of use of existing peptides and monoclonal antibodies are limited, and small-molecule bone formation–promoting drugs are urgently required. We established an I-9 synthesis route with high yield, simple operation, and low cost that was suitable for future large-scale production. I-9 administration promoted bone formation and increased bone mass in mice with low bone mass in an aged C57 mouse model. Our findings revealed a hitherto undescribed pathway involving the BMP2–ERK–ATF4 axis that promotes osteoblast differentiation; I-9 has favorable biosafety in mice. This study systematically investigated the efficacy, safety, and mechanism of I-9 for treating osteoporosis and positions this drug for preclinical research in the future. Thus, this study has promoted the development of small-molecule bone-promoting drugs.
biochemistry & molecular biology,chemistry, multidisciplinary
What problem does this paper attempt to address?
This paper aims to address the demand for bone formation-promoting drugs for osteoporosis patients in an aging society. Specifically, the existing first-line clinical drugs are mainly those that inhibit bone resorption, and these drugs are difficult to restore the bone mass of the elderly to a safe range. Existing peptide and monoclonal antibody drugs have limitations in terms of usage scope and duration, and there is an urgent need for small molecule bone formation-promoting drugs. The paper attempts to develop a new small molecule drug to promote bone formation by studying the mechanism of action of compound I-9 and its efficacy and safety in the treatment of osteoporosis. The research found that I-9 can promote osteoblast differentiation through the BMP2–ERK–ATF4 axis and showed good biosafety in an elderly mouse model. Therefore, this study systematically explored the efficacy, safety, and mechanism of action of I-9, laying the foundation for further preclinical research.